Raptor Pharmaceutical (RPTP) 7.83 $RPTP
Raptor Pharmaceutical Reports First Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 08, 3:48PM CDT
Reports PROCYSBI net product sales of $12.1 million in first quarter 2014 and launch of PROCYSBI in Germany
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Raptor Pharmaceutical to Present at Upcoming Investor Conference
GlobeNewswire - Thu May 01, 6:41AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 14, 2014 at 5:00 p.m. PDT/8:00 p.m. EDT. Julie Anne Smith, SVP and COO at Raptor, will present an update on the PROCYSBI commercial rollout and program updates. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Raptor Pharmaceutical to Hold First Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Wed Apr 30, 3:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release first quarter 2014 financial results after market close on Thursday, May 8, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
4 Stocks Under $10 Moving Higher
at The Street - Wed Apr 09, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services
Business Wire - Fri Apr 04, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals for Leigh Syndrome and Other Mitochondrial Disorders
Business Wire - Tue Mar 25, 6:30AM CDT
Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Akorn, Inc. (NASDAQ: AKRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Plug Power, Aeropostale, and Raptor Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 14, 7:30PM CDT
Friday's market action involved many of the same concerns that have plagued stock investors all week, including the planned referendum in Crimea on whether to break off from Ukraine and join Russia. Nervousness led to small declines for broad market...
Why Raptor Pharmaceuticals Corp. Shares Cratered
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 1:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Raptor Pharmaceuticals , a...
Raptor Pharma Posts Wider-Than-Expected Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 10:40AM CDT
The company posted a loss of 22 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 17 cents per share.
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:05PM CDT
2014 guidance of $55-$65 million of net sales for PROCYSBI
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close on Thursday, March 13, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 24, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Raptor Pharmaceutical Reports First Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 08, 3:48PM CDT
Reports PROCYSBI net product sales of $12.1 million in first quarter 2014 and launch of PROCYSBI in Germany
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Raptor Pharmaceutical to Present at Upcoming Investor Conference
GlobeNewswire - Thu May 01, 6:41AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 14, 2014 at 5:00 p.m. PDT/8:00 p.m. EDT. Julie Anne Smith, SVP and COO at Raptor, will present an update on the PROCYSBI commercial rollout and program updates. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Raptor Pharmaceutical to Hold First Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Wed Apr 30, 3:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release first quarter 2014 financial results after market close on Thursday, May 8, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
4 Stocks Under $10 Moving Higher
at The Street - Wed Apr 09, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services
Business Wire - Fri Apr 04, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals for Leigh Syndrome and Other Mitochondrial Disorders
Business Wire - Tue Mar 25, 6:30AM CDT
Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Akorn, Inc. (NASDAQ: AKRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Plug Power, Aeropostale, and Raptor Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 14, 7:30PM CDT
Friday's market action involved many of the same concerns that have plagued stock investors all week, including the planned referendum in Crimea on whether to break off from Ukraine and join Russia. Nervousness led to small declines for broad market...
Why Raptor Pharmaceuticals Corp. Shares Cratered
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 1:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Raptor Pharmaceuticals , a...
Raptor Pharma Posts Wider-Than-Expected Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 10:40AM CDT
The company posted a loss of 22 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 17 cents per share.
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:05PM CDT
2014 guidance of $55-$65 million of net sales for PROCYSBI
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close on Thursday, March 13, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 24, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences.
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
